ZimVie — Q1 2025 Earnings Presentation
16 slides from ZimVie's earnings presentation, May 8, 2025
Slide 1: A Global Dental Leader
Exhibit 99.2 A Global Dental Leader May 2025 1
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans
Slide 3: ZimVie: A Global Dental Leader
ZimVie: A Global Dental Leader Market-leading portfolio of Only 25% premium implants, restorative receive tooth implant solutions, biomaterials replacement solutions, and digital dentistry technologies 8M Leading with differentiated technology and continuing to U.S. patients seek treatment for inves
Slide 4: Dental Implants: Portfolio Overview
Dental Implants: Portfolio Overview ® TSX Implant System Launched in 2022, TSX Implants are designed to simplify procedures and optimize practice protocols to deliver peri-implant health, crestal bone maintenance, long-term osseointegration, and prosthetic stability. Key Products & Brands ® T3 PRO I
Slide 5: Biomaterials: Portfolio Overview
Biomaterials: Portfolio Overview ® Puros Allograft Products Human-donor sourced bone graft material with premium proprietary processing used to replace missing or damaged bone to provide a Key Products foundation for the implant and create desirable aesthetic outcomes. & Brands ® Puros Allograft Bon
Slide 6: Digital: Portfolio Overview
Digital: Portfolio Overview ® RealGUIDE Software Software suite that offers precise planning, designing, and predictable placement of dental implants and restorations, helping users manage procedural risk more effectively and plan complex cases in a fraction Key Products of the time. & Brands ® Bell
Slide 7: Revitalizing the Portfolio with Recent Launches
Revitalizing the Portfolio with Recent Launches Dental Implants Biomaterials Digital Dentistry ® ® TSX and T3 PRO Immediate Molar Implant Systems ® RegenerOss ® ® RegenerOss RealGUIDE 5.4 CAD/CAM Workflow Cortico–Cancellous Bone Graft Plug Systems Software Particulate Azure Multi-Platform Solutions
Slide 8: End-to-End Solutions Save Time and Improve the Clinician and Patient Experience
End-to-End Solutions Save Time and Improve the Clinician and Patient Experience Virtual Treatment Planning Dental Software & Digitally Guided Surgical Kits • AI-facilitated restorative solutions require significantly * fewer labor hours • ZimVie Encode Emergence workflow reduces chair time and saves
Slide 9: 1Q25 Achievements: Driving Leverage and Operationalization
1Q25 Achievements: Driving Leverage and Operationalization M E T R I C 1 Q 2 5 * 1 Q 2 4 * C H A N G E Net Sales $112.0M $118.2M ($6.2M)(5.2%) (2) Adjusted Cost of Products Sold as a % of (1) (1) 33.6% 37.2% +360bps Sales (1) (1) Adjusted EBITDA $17.6M $12.5M +$5.1M (41%) (1) (1) Adjusted EPS $0.27
Slide 10: Financial Profile & Outlook
Financial Profile & Outlook Reported Drivers of Progress (2) Q1 2025* FY 2025* CC Growth* Growth* Best-in-class portfolio and commitment to ongoing innovation Net Sales $112.0M $445M - $460M (1%) – 2% Flat – 3% Expanding portfolio adoption within large, underserved dental (1) (2) (2) 8% – 17% $17.6M
Slide 11: Appendix
Appendix 11 Confidential
Slide 12: Note on Non-GAAP Financial Measures
Note on Non-GAAP Financial Measures This presentation includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non- GAAP financial measures may not be comparable to similar measures reported b
Slide 13: Reconciliation of Adjusted Cost of Products Sold (Excluding Intangible Asset Amortization)
Reconciliation of Adjusted Cost of Products Sold (Excluding Intangible Asset Amortization) Continuing Operations ($ in thousands) For the Three Months Ended March 31 Percentage of Net Sales 2025 2024 2025 2024 Cost of products sold, excluding intangible asset amortization $ (37,949) $ (44,258) (33.9
Slide 14: Reconciliation of Adjusted R&D and Adjusted SG&A
Reconciliation of Adjusted R&D and Adjusted SG&A Continuing Operations ($ in thousands) For the Three Months Ended March 31 Percentage of Net Sales 2025 2024 2025 2024 Research and development $ (5,371) $ (6,701) (4.8%) (5.7%) [1] European Union medical device regulation - 401 0.0% 0.4% Adjusted cos
Slide 15: Reconciliation of Adjusted EBITDA
Reconciliation of Adjusted EBITDA Continuing Operations ($ in thousands) For the Three Months Ended March 31 2025 2024 Net Sales $ 111,997 $ 118,195 Net Loss $ (2,625) $ (11,483) Interest expense, net 2,017 4,366 Income tax provision 3,074 4,074 Depreciation and amortization 8,655 8,430 EBITDA 11,12
Slide 16: Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS
Reconciliation of Adjusted Net (Loss) Income and Adjusted EPS Continuing Operations (in thousands, except per share data) For the Three Months Ended March 31, 2025 Cost of products Operating sold, excluding expenses, intangible asset excluding cost of Net Sales amortization products sold Operating I